Table 2.
Relationship between systemic inflammatory markers and clinicopathologic features in patients with non-small cell lung carcinoma.
| NLR | PLR | LMR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low (n = 82) |
High (n = 81) |
p | Low (n = 81) |
High (n = 82) |
p | Low (n = 81) |
High (n = 82) |
p | |
| Age (years) | 65.5 ± 9.3 | 64.0 ± 10.5 | 0.353 | 65.3 ± 9.1 | 64.3 ± 10.7 | 0.511 | 65.2 ± 10.5 | 64.3 ± 9.4 | 0.552 |
| Sex | |||||||||
| Male (n = 111, 68.1%) | 30 (36.6%) | 59 (72.8%) | 0.262 | 55 (67.9%) | 56 (68.3%) | 0.999 | 64 (79.0%) | 47 (57.3%) | 0.005 |
| Female (n = 52, 31.9%) | 52 (63.4%) | 22 (27.2%) | 26 (32.1%) | 26 (31.7%) | 17 (21.0%) | 35 (42.7%) | |||
| Smoking Status | |||||||||
| Never smoker (n = 71, 43.6%) | 40 (48.8%) | 31 (38.3%) | 0.232 | 43 (53.1%) | 33 (40.2%) | 0.483 | 32 (39.5%) | 39 (47.6%) | 0.379 |
| Ever smoker (n = 92, 56.4%) | 42 (51.2%) | 50 (61.7%) | 38 (46.9%) | 49 (59.8%) | 49 (60.5%) | 43 (52.4% | |||
| Histology | |||||||||
| Non-SqCC (n = 115 70.6%) | 62 (75.6%) | 52 (64.2%) | 0.156 | 52 (64.2%) | 62 (75.6%) | 0.156 | 54 (66.7%) | 60 (73.2%) | 0.463 |
| SqCC (n = 48, 29.4%) | 20 (24.4%) | 29 (35.8%) | 29 (35.8%) | 20 (24.4%) | 27 (33.3%) | 22 (26.8%) | |||
| Tumor differentiation | |||||||||
| WD and MD (n = 133, 81.6%) | 69 (84.1%) | 64 (79.0%) | 0.52 | 69 (85.2%) | 64 (78.0%) | 0.33 | 62 (76.5%) | 71 (86.6%) | 0.146 |
| PD (n = 30, 18.4%) | 13 (15.9%) | 17 (21.0%) | 12 (14.8%) | 18 (22.0%) | 19 (23.5%) | 11 (13.4%) | |||
| Lymphovascular invasion | |||||||||
| Absent (n = 125, 76.7%) | 66 (80.5%) | 59 (72.8%) | 0.332 | 65 (80.2%) | 60 (73.2%) | 0.377 | 63 (77.8%) | 62 (75.6%) | 0.887 |
| Present (n = 38, 23.3%) | 16 (19.5%) | 22 (27.2%) | 16 (19.8%) | 22 (26.8%) | 18 (22.2%) | 20 (24.4%) | |||
| T stage * | |||||||||
| 1 (n = 50, 30.7%) | 30 (40.0%) | 20 (31.7%) | 0.138 | 28 (38.4%) | 22 (33.8%) | 0.156 | 22 (34.9%) | 28 (37.3%) | 0.693 |
| 2 (n = 66, 40.5%) | 38 (50.7%) | 28 (44.4%) | 34 (46.6%) | 32 (49.2%) | 30 (47.6%) | 36 (48.0%) | |||
| 3 (n = 18, 6.7%) | 6 ( 8.0%) | 12 (19.0%) | 11 (15.1%) | 7 (10.8%) | 8 (12.7%) | 10 (13.3%) | |||
| 4 (n = 4, 2.5%) | 1 ( 1.3%) | 3 ( 4.8%) | 0 ( 0.0%) | 4 ( 6.2%) | 3 ( 4.8%) | 1 ( 1.3%) | |||
| N stage † | |||||||||
| 0 (n = 77, 47.2%) | 47 (62.7%) | 30 (48.4%) | 0.145 | 40 (55.6%) | 37 (56.9%) | 0.784 | 34 (54.0%) | 43 (58.1%) | 0.626 |
| 1 (n = 30, 18.4%) | 16 (21.3%) | 14 (22.6%) | 15 (20.8%) | 15 (23.1%) | 13 (20.6%) | 17 (23.0%) | |||
| 2 (n = 29, 17.8%) | 11 (14.7%) | 18 (29.0%) | 16 (22.2%) | 13 (20.0%) | 15 (23.8%) | 14 (18.9%) | |||
| 3 (n = 1, 0.6%) | 1 ( 1.3%) | 0 ( 0.0%) | 1 ( 1.4%) | 0 ( 0.0%) | 1 ( 1.6%) | 0 ( 0.0%) | |||
| AJCC Stage | |||||||||
| I (n = 62, 38.0%) | 40 (48.8%) | 22 (27.2%) | 0.012 | 34 (42.0%) | 28 (34.1%) | 0.207 | 26 (32.1%) | 36 (43.9%) | 0.032 |
| II (n = 41, 25.2%) | 21 (25.6%) | 20 (24.7%) | 21 (25.9%) | 20 (24.4%) | 17 (21.0%) | 24 (29.3%) | |||
| III (n = 34, 20.9%) | 13 (15.9%) | 21 (25.9%) | 18 (22.2%) | 16 (19.5%) | 19 (23.5%) | 15 (18.3%) | |||
| IV (n = 30, 18.4%) | 8 ( 9.8%) | 18 (22.2%) | 8 ( 9.9%) | 18 (22.0%) | 19 (23.5%) | 7 ( 8.5%) | |||
| SUVmax | 5.5 ± 3.5 | 7.3 ± 3.9 | 0.003 | 5.5 ± 3.6 | 7.3 ± 3.8 | 0.004 | 7.0 ± 3.8 | 5.8 ± 3.8 | 0.032 |
| NLR | - | - | - | 1.6 ± 0.7 | 4.0 ± 3.8 | <0.001 | 3.8 ± 3.6 | 1.8 ± 1.7 | <0.001 |
| PLR | 96.5 ± 32.2 | 171.5 ± 103.2 | <0.001 | - | - | - | 166.2 ± 104.8 | 101.7 ± 38.0 | <0.001 |
| LMR | 4.8 ± 1.8 | 3.2 ± 1.4 | <0.001 | 4.9 ± 1.9 | 3.2 ± 1.2 | <0.001 | - | - | - |
SqCC—squamous cell carcinoma; WD—well differentiated; MD—moderately differentiated; PD—poorly differentiated; AJCC—American Joint Committee on Cancer; SUVmax—maximum standardized uptake value; NLR—neutrophil–lymphocyte ratio; PLR—platelet–lymphocyte ratio; LMR—lymphocyte–monocyte ratio. * Twenty-five patients have missing pathologic T stage data. † Twenty-six patients have missing pathologic N stage data.